{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:52:25Z","timestamp":1793764345482,"version":"4.6.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["105-2314-B-038-043-MY3"],"award-info":[{"award-number":["105-2314-B-038-043-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["104-2314-B-038-037"],"award-info":[{"award-number":["104-2314-B-038-037"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.psychres.2019.03.007","type":"journal-article","created":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T21:04:54Z","timestamp":1551819894000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Obsessive-compulsive symptoms in patients with schizophrenia: Relationships with olanzapine pharmacological parameters, psychopathology, and quality of life"],"prefix":"10.1016","volume":"276","author":[{"given":"Tzu-Hua","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Chiang","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2926-1031","authenticated-orcid":false,"given":"Po-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chyi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Hsin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston W.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mong-Liang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.psychres.2019.03.007_bib0001","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/schbul\/sbp148","article-title":"How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association","volume":"37","author":"Achim","year":"2011","journal-title":"Schizophr. Bull."},{"issue":"1-2","key":"10.1016\/j.psychres.2019.03.007_bib0002","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0166-4328(01)00297-2","article-title":"Controlling the false discovery rate in behavior genetics research","volume":"125","author":"Benjamini","year":"2001","journal-title":"Behav. Brain Res."},{"issue":"1","key":"10.1016\/j.psychres.2019.03.007_bib0003","first-page":"37","article-title":"Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain","volume":"26","author":"Blier","year":"2001","journal-title":"J. Psychiatry Neurosci."},{"issue":"2","key":"10.1016\/j.psychres.2019.03.007_bib0004","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0165-1781(00)00203-1","article-title":"Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial","volume":"96","author":"Bogetto","year":"2000","journal-title":"Psychiatry Res."},{"issue":"2-3","key":"10.1016\/j.psychres.2019.03.007_bib0005","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.psychres.2010.07.048","article-title":"Factor structure of the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) in a large sample of patients with schizophrenia or related disorders and comorbid obsessive-compulsive symptoms","volume":"186","author":"Boyette","year":"2011","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.psychres.2019.03.007_bib0006","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4088\/JCP.07r03618","article-title":"Relationships between obsessive-compulsive symptomatology and severity of psychosis in schizophrenia: a systematic review and meta-analysis","volume":"70","author":"Cunill","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2019.03.007_bib0007","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.psychres.2013.05.029","article-title":"The effect of obsessive-compulsive symptomatology on executive functions in schizophrenia: a systematic review and meta-analysis","volume":"210","author":"Cunill","year":"2013","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.psychres.2019.03.007_bib0008","doi-asserted-by":"crossref","first-page":"25","DOI":"10.64719\/pb.4154","article-title":"Reliability and validity of the Yale-Brown Obsessive-Compulsive Scale in schizophrenia patients","volume":"39","author":"de Haan","year":"2006","journal-title":"Psychopharmacol. Bull."},{"issue":"1","key":"10.1016\/j.psychres.2019.03.007_bib0009","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/schbul\/sbr077","article-title":"The 5-year course of obsessive-compulsive symptoms and obsessive-compulsive disorder in first-episode schizophrenia and related disorders","volume":"39","author":"de Haan","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2019.03.007_bib0010","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.comppsych.2014.09.015","article-title":"Prevalence and clinical correlates of obsessive-compulsive disorder in schizophrenia","volume":"56","author":"Devi","year":"2015","journal-title":"Compr. Psychiatry"},{"issue":"1-2","key":"10.1016\/j.psychres.2019.03.007_bib0011","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.psychres.2012.02.024","article-title":"Age-of-onset of schizophrenic and obsessive-compulsive symptoms in patients with schizo-obsessive disorder","volume":"197","author":"Faragian","year":"2012","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psychres.2019.03.007_bib0012","first-page":"1","article-title":"Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia","author":"Fernandez-Egea","year":"2018","journal-title":"Psychol. Med."},{"issue":"4","key":"10.1016\/j.psychres.2019.03.007_bib0013","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/JCP.0000000000000521","article-title":"Fluoxetine adjunctive yherapy for obsessive-compulsive symptoms associated with olanzapine in schizophrenic patients","volume":"36","author":"Figueiredo","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.psychres.2019.03.007_bib0014","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","article-title":"The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability","volume":"46","author":"Goodman","year":"1989","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.psychres.2019.03.007_bib0015","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.psychres.2016.09.031","article-title":"Induced obsessive compulsive symptoms (OCS) in schizophrenia patients under atypical 2 antipsychotics (AAPs): review and hypotheses","volume":"246","author":"Grillault Laroche","year":"2016","journal-title":"Psychiatry Res."},{"issue":"12","key":"10.1016\/j.psychres.2019.03.007_bib0016","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1176\/ajp.143.12.1527","article-title":"Obsessive-compulsive disorder with psychotic features: a phenomenologic analysis","volume":"143","author":"Insel","year":"1986","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2019.03.007_bib0017","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.psychres.2019.03.007_bib0018","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.psychres.2015.01.021","article-title":"Associations of obsessive-compulsive symptoms with clinical and neurocognitive features in schizophrenia according to stage of illness","volume":"226","author":"Kim","year":"2015","journal-title":"Psychiatry Res."},{"issue":"4","key":"10.1016\/j.psychres.2019.03.007_bib0019","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/WNF.0b013e318184fafd","article-title":"The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia","volume":"32","author":"Kim","year":"2009","journal-title":"Clin. Neuropharmacol."},{"issue":"6","key":"10.1016\/j.psychres.2019.03.007_bib0020","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1097\/JCP.0b013e31815a584c","article-title":"Prevalence and clinical characteristics of obsessive-compulsive symptoms associated with atypical antipsychotics","volume":"27","author":"Lim","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.psychres.2019.03.007_bib0021","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/01.ftd.0000211801.66569.80","article-title":"Higher plasma drug concentration in clozapine-treated schizophrenic patients with side effects of obsessive\/compulsive symptoms","volume":"28","author":"Lin","year":"2006","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.psychres.2019.03.007_bib0022","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.schres.2017.07.022","article-title":"Application of plasma levels of olanzapine and N-desmethyl-olanzapine to monitor metabolic parameters in patients with schizophrenia","volume":"193","author":"Lu","year":"2018","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.psychres.2019.03.007_bib0023","doi-asserted-by":"crossref","first-page":"e65719","DOI":"10.1371\/journal.pone.0065719","article-title":"Determination of olanzapine and N-desmethyl-olanzapine in plasma using a reversed-phase HPLC coupled with coulochemical detection: correlation of olanzapine or N-desmethyl-olanzapine concentration with metabolic parameters","volume":"8","author":"Lu","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.psychres.2019.03.007_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148539","article-title":"Application of plasma levels of olanzapine and N-desmethyl-olanzapine to monitor clinical efficacy in patients with schizophrenia","volume":"11","author":"Lu","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.psychres.2019.03.007_bib1034","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0278-5846(03)00039-3","article-title":"Obsessive-compulsive symptoms induced by atypical antipsychotics. A review of the reported cases","volume":"27","author":"Lykouras","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2019.03.007_bib0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.psychres.2005.10.005","article-title":"Lower levels of whole blood serotonin in obsessive-compulsive disorder and in schizophrenia with obsessive-compulsive symptoms","volume":"150","author":"Ma","year":"2007","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psychres.2019.03.007_bib0026","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiol. Rev."},{"key":"10.1016\/j.psychres.2019.03.007_bib0027","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"issue":"2-3","key":"10.1016\/j.psychres.2019.03.007_bib0028","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.schres.2004.08.012","article-title":"Obsessive-compulsive symptoms in schizophrenia: associated clinical features, cognitive function and medication status","volume":"75","author":"Ongur","year":"2005","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.psychres.2019.03.007_bib0029","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/13651501.2017.1330417","article-title":"Obsessive-compulsive symptoms in schizophrenia: prevalence and associated factors in a Nigerian population","volume":"21","author":"Opakunle","year":"2017","journal-title":"Int. J. Psychiatry Clin. Pract."},{"issue":"3","key":"10.1016\/j.psychres.2019.03.007_bib0030","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.psychres.2009.08.003","article-title":"Obsessive-compulsive disorder and obsessive-compulsive symptoms in Japanese inpatients with chronic schizophrenia \u2013 a possible schizophrenic subtype","volume":"179","author":"Owashi","year":"2010","journal-title":"Psychiatry Res."},{"issue":"3","key":"10.1016\/j.psychres.2019.03.007_bib0031","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00004850-200015030-00006","article-title":"Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms","volume":"15","author":"Poyurovsky","year":"2000","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2019.03.007_bib0032","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/mp.2008.94","article-title":"The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication","volume":"15","author":"Ruscio","year":"2010","journal-title":"Mol. Psychiatry"},{"issue":"11","key":"10.1016\/j.psychres.2019.03.007_bib0033","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.4088\/JCP.11m07164","article-title":"Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients","volume":"73","author":"Scheltema Beduin","year":"2012","journal-title":"J. Clin. Psychiatry"},{"issue":"11","key":"10.1016\/j.psychres.2019.03.007_bib0034","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1017\/S0033291711000419","article-title":"Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia","volume":"41","author":"Schirmbeck","year":"2011","journal-title":"Psychol. Med."},{"issue":"4","key":"10.1016\/j.psychres.2019.03.007_bib0035","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1177\/0269881112463470","article-title":"Differential effects of antipsychotic agents on obsessive-compulsive symptoms in schizophrenia: a longitudinal study","volume":"27","author":"Schirmbeck","year":"2013","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2019.03.007_bib0036","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fphar.2013.00099","article-title":"Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors","volume":"4","author":"Schirmbeck","year":"2013","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.psychres.2019.03.007_bib0037","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/00007691-200208000-00010","article-title":"Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting","volume":"24","author":"Skogh","year":"2002","journal-title":"Ther. Drug Monit."},{"issue":"2-3","key":"10.1016\/j.psychres.2019.03.007_bib0038","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.schres.2013.10.033","article-title":"The obsessive compulsive spectrum in schizophrenia, a meta-analysis and meta-regression exploring prevalence rates","volume":"152","author":"Swets","year":"2014","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.psychres.2019.03.007_bib0039","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.psychres.2015.07.089","article-title":"Suicidality in clozapine-treated patients with schizophrenia: role of obsessive-compulsive symptoms","volume":"230","author":"Szmulewicz","year":"2015","journal-title":"Psychiatry Res."},{"issue":"3","key":"10.1016\/j.psychres.2019.03.007_bib0040","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1017\/S0033291798006667","article-title":"Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group","volume":"28","year":"1998","journal-title":"Psychol. Med."},{"issue":"1","key":"10.1016\/j.psychres.2019.03.007_bib0041","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00406-015-0608-y","article-title":"Obsessive-compulsive symptom severity in schizophrenia: a Janus Bifrons effect on functioning","volume":"266","author":"Tonna","year":"2016","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"4","key":"10.1016\/j.psychres.2019.03.007_bib0042","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3109\/13651501.2014.943243","article-title":"Obsessive compulsive symptoms are related to lower quality of life in patients with Schizophrenia","volume":"18","author":"Ucok","year":"2014","journal-title":"Int. J. Psychiatry Clin. Pract."},{"issue":"5","key":"10.1016\/j.psychres.2019.03.007_bib0043","first-page":"342","article-title":"Development and verification of validity and reliability of the WHOQOL-BREF Taiwan version","volume":"101","author":"Yao","year":"2002","journal-title":"J. Formos. Med. Assoc."},{"issue":"5","key":"10.1016\/j.psychres.2019.03.007_bib0044","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/JCP.0000000000000770","article-title":"A pilot study of the usefulness of a single olanzapine plasma concentration as an indicator of early drug effect in a small sample of first-episode psychosis patients","volume":"37","author":"Zabala","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2019.03.007_bib0045","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/317980","article-title":"Comorbid obsessive-compulsive symptoms in schizophrenia: insight into pathomechanisms facilitates treatment","volume":"2014","author":"Zink","year":"2014","journal-title":"Adv. Med."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178118316470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178118316470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:34:26Z","timestamp":1777494866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178118316470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":46,"alternative-id":["S0165178118316470"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2019.03.007","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obsessive-compulsive symptoms in patients with schizophrenia: Relationships with olanzapine pharmacological parameters, psychopathology, and quality of life","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2019.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}